DSM Pharmaceuticals Inc. names new CEO

27-Feb-2002

DSM announces today the appointment of Mr Wesley P. Wheeler as President & CEO, DSM Pharmaceuticals Inc. (former DSM Catalytica Pharmaceuticals), as well as Business Unit Director Dose Manufacturing and Supply. Wes Wheeler succeeds Michael Thomas, who will leave DSM. Mr Wheeler will assume responsibility mid March, 2002. Experience Mr Wheeler is currently Senior Vice President in GlaxoSmithKline's Global Manufacturing & Supply organization, based in Research Triangle Park, NC. Prior to his senior role in manufacturing, Mr Wheeler served as Vice President Marketing; Group Director Marketing services and Director Engineering. Mr Wheeler worked at Exxon (Esso) for twelve years prior to joining GlaxoSmithKline in 1989. Next phase "We are excited about Wes joining DSM, as his energy and experience will lead our business in DSM Pharmaceuticals into the next phase", said Feike Sijbesma, member of DSM's Managing Board. Catalytica Pharmaceuticals Inc. (Greenville, North Carolina, USA) was acquired by DSM in 2001 and in so doing further expanded its leading role as a partner and supplier to the pharmaceutical industry. DSM offers chemical intermediates, active pharmaceutical ingredients (API), dosage form manufacturing, finished goods packaging and development services. DSM Pharmaceuticals Inc. operates one of the industry's most advanced sterile manufacturing plants, and is capable of producing most other dose forms. DSM also produces biopharmaceutical products at its plants in Montreal (Canada) and Groningen (Netherlands). "We regret Wes's departure from GSK, but this is an excellent opportunity for him, and we look forward to building further on our relationship with DSM", said Tim Tyson, President, Global Manufacturing & Supply, GlaxoSmithKline.

https://www.chemeurope.com/en/news/8888/dsm-pharmaceuticals-inc-names-new-ceo.html